Our survival analysis of 1926 NSCLC patients [26] revealed that the OS rate of NSCLC patients with high expression of PLK1 (median survival 45.8 months) was lower than that of NSCLC patients with low PLK1 expression (median survival 89 months) with high significance (n = 1926, HR = 1.66, log rank p = 3.3e-15) (Fig. 1b, left panel). Here, PLK1 is linked to non-small cell lung carcinoma.